Evidence map›Paper›PMID 15314691›Full record

ArticleThe Journal of clinical investigation2004

Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo.

Tihui Fu, Kui Shin Voo, Rong-Fu Wang

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Cytotoxic CD4Frontiers in immunology · 2023
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. The clinicopathologic spectrum of mature aggressive B cell lymphomas.Virchows Archiv : an international journal of pathology · 2017
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Tihui FuThe Center for Cell and Gene Therapy and Department of Immunology, Baylor College of Medicine, Houston, TX 77030, USA.
Kui Shin Voo
Rong-Fu Wang
Baylor College of Medicine · USGenomic (Brazil) · BR

Funding

VECTOR PRODUCTIONP01CA094237 · NCI · BAYLOR COLLEGE OF MEDICINE · PI HESLOP, HELEN E, ROONEY, CLIONA M. · 2002 to 2017
$27.8M
The Role of CD4+ T Cells in Antitumor ImmunityR01CA090327 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WANG, RONGFU · 2002 to 2013
$3.0M
NCI NIH HHS CA 90327NCI NIH HHS CA 94237NCI NIH HHS P01 CA094237NCI NIH HHS R01 CA090327
6 · The paper itself

Abstract

CD4+ T cells play important roles in orchestrating host immune responses against cancer and infectious diseases. Although EBV-encoded nuclear antigen 1-specific (EBNA1-specific) CD4+ T cells have been implicated in controlling the growth of EBV-associated tumors such as Burkitt lymphoma (BL) in vitro, direct evidence for their in vivo function remains elusive due to the lack of an appropriate experimental BL model. Here, we describe the development of a mouse EBNA1-expressing BL tumor model and the identification of 2 novel MHC H-2I-A(b)-restricted T cell epitopes derived from EBNA1. Using our murine BL tumor model and the relevant peptides, we show that vaccination of mice with EBNA1 peptide-loaded DCs can elicit CD4+ T cell responses. These EBNA1-specific CD4+ T cells recognized peptide-pulsed targets as well as EBNA1-expressing tumor cells and were necessary and sufficient for suppressing tumor growth in vivo. By contrast, EBNA1 peptide-reactive CD8+ T cells failed to recognize tumor cells and did not contribute to protective immunity. These studies represent what we believe to be the first demonstration that EBNA1-specific CD4+ T cells can suppress tumor growth in vivo, which suggests that CD4+ T cells play an important role in generating protective immunity against EBV-associated cancer.

Indexed as

AnimalsAntibodies, MonoclonalBurkitt LymphomaCD4 AntigensCD4-Positive T-LymphocytesCell Line, TumorDisease Models, AnimalEpitopesEpstein-Barr Virus Nuclear AntigensFemaleMiceMice, Inbred C57BLMice, KnockoutNeoplasm TransplantationRetroviridaeSensitivity and SpecificityAntibodies, MonoclonalCD4 AntigensEBV-encoded nuclear antigen 1EpitopesEpstein-Barr Virus Nuclear Antigens

Identifiers

PMID15314691
PMCPMC503775
OpenAlexW2077224215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.